Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company with operations in the Netherlands, the United States, and China, has formed a strategic partnership with Ingenia Therapeutics, a pre-clinical biotech with a presence in the United States and South Korea. The collaboration aims to expedite the development of innovative therapeutics for immunological disorders that have significant unmet medical needs, although no financial details of the partnership were disclosed.
Nona Bio’s Commitment to Innovation
Nona Biosciences is a global biotechnology firm dedicated to cutting-edge technological innovation. The company offers a comprehensive solution that spans from “Idea to IND” (I to I), encompassing target validation, antibody discovery, and preclinical research. This end-to-end approach positions Nona Bio at the forefront of biotech innovation.
Ingenia’s Microvasculature Protection Technology
Ingenia Therapeutics, a privately held company, specializes in proprietary microvasculature protection technology. This technology is designed to rehabilitate and protect defective blood vessels against a range of microvascular destabilizing factors, including VEGF, pro-inflammatory cytokines, and elevated blood glucose levels. The partnership with Nona Biosciences is expected to leverage Ingenia’s expertise in this area to develop novel treatments for immunological disorders.-Fineline Info & Tech
